Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date

PARP inhibitors have shown significant promise in the treatment of ovarian cancer. Olaparib is a PARP inhibitor that has been approved for maintenance for BRCA-mutated ovarian cancer in the recurrent and front-line setting as well as for treatment of BRCA-mutated ovarian cancer in patients who have...

Descripción completa

Detalles Bibliográficos
Autores principales: Montemorano, Lauren, Lightfoot, Michelle DS, Bixel, Kristin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938196/
https://www.ncbi.nlm.nih.gov/pubmed/31920338
http://dx.doi.org/10.2147/OTT.S195552
Descripción
Sumario:PARP inhibitors have shown significant promise in the treatment of ovarian cancer. Olaparib is a PARP inhibitor that has been approved for maintenance for BRCA-mutated ovarian cancer in the recurrent and front-line setting as well as for treatment of BRCA-mutated ovarian cancer in patients who have received multiple prior lines of chemotherapy. In this review, we focus on the use of olaparib in the maintenance setting including the evidence to date, ongoing research, and future directions.

Ejemplares similares